Core Viewpoint - The company Huate Dain (000915.SZ) has begun online sales of its children's melatonin product, Manlejing, on platforms such as JD.com and Alibaba, with plans for offline sales in hospitals across China [1] Group 1 - The company reports that its production, operations, and sales are currently normal [1] - The company's stock price fluctuations are influenced by various macroeconomic factors [1] - The company aims to focus on its core business to enhance its competitive strength and deliver good operating results to investors [1]

Investment Rating - The report maintains a "Buy" rating for the company, indicating an expected relative price increase of over 20% against the market benchmark within the next six months [6][18]. Core Views - The company achieved a revenue of 1.17 billion yuan in H1 2025, reflecting a year-on-year growth of 1.39%, with a net profit of 337 million yuan, up 1.69% year-on-year. The net profit margin reached a historical high of 28.83% [3][6]. - The company continues to focus on its core pediatric pharmaceutical business, with its subsidiary, Dain Pharmaceutical, contributing 98.6% of the consolidated revenue [3]. - The company has signed an exclusive distribution agreement for Melatonin Granules (Manlejing®), enhancing its pediatric product portfolio and addressing a significant clinical need in the market [4][5]. Financial Performance - In Q2 2025, the company reported a revenue of 554 million yuan, down 4.88% year-on-year, and a net profit of 155 million yuan, down 4.97% year-on-year. The gross margin was 85.19%, a decrease of 2.01 percentage points year-on-year [3]. - The company forecasts revenues of 2.37 billion yuan, 2.64 billion yuan, and 2.94 billion yuan for 2025, 2026, and 2027 respectively, with growth rates of 11% for both 2025 and 2026, and 12% for 2027 [6][8]. - The net profit is projected to be 550 million yuan, 610 million yuan, and 682 million yuan for the same years, with growth rates of 7% for 2025, 11% for 2026, and 12% for 2027 [6][8]. Product Development and Market Position - The company's flagship product, "Yikexin Vitamin AD Drops," maintains a high market share and leadership position, while the product matrix continues to expand with new offerings such as Dain Iron and Dain Calcium [5]. - The marketing strategy targeting children aged 0-18 has shown positive results, with significant sales growth in specific product lines [5].

Core Viewpoint - Huate Dain (000915.SZ) has signed an exclusive distribution agreement with Nobelpharma Co., Ltd for melatonin granules (brand name: Manlejing®) in mainland China, marking a significant step in addressing the treatment gap for sleep difficulties in children with neurodevelopmental disorders [1] Group 1 - Huate Dain's subsidiary, Beijing Dain Kangjian Pharmaceutical Co., Ltd, will be the exclusive distributor for Manlejing® in mainland China, excluding Hong Kong, Macau, and Taiwan [1] - The product is set to be approved for market launch in China by July 2025, targeting children aged 6-15 with sleep difficulties [1] - This agreement allows Huate Dain to manage the import, marketing, and sales of the product, fulfilling a critical clinical need in the domestic market [1]